All News

ORAL Surveillance: MACE events higher in TOFA vs TNFi. Independent risk factors: smoking, aspirin use, age ≥ 65 yrs, and male sex; TOFA vs TNFi tx in these pts assoc'd w/ numerically higher MACE incidence. Plenary Abs 0958 #ACR21 #ACRbest @RheumNow https://t.co/44af1KujqP

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

Keep the Hydroxychloroquine! SLICC cohort eval flare risk in 1460 pts who⬇️or d/c HCQ: 👉pts in remission who d/c HCQ flared HR 2.77 (1.46,5.26) 👉pts in remission who⬇️dose flared HR 2.14 (1.34, 3.42) Abst#0959 #Plenary #ACR21 @rheumnow #ACRbest https://t.co/92U215s8IP
TheDaoIndex KDAO2011 ( View Tweet)
Controversial from John Stone at #ACR21 . Any thoughts @docrota @drhectorchinoy ? @RheumNow https://t.co/vBnolnQ7WV
Richard Conway RichardPAConway ( View Tweet)
Do you order EKGs in everyone starting HCQ? Do you avoid HCQ in patients with heart failure? Will these abstracts impact your practice? Click on link to read more....#ACR21 @rheumnow #HCQ https://t.co/fvUZAvNWa8

Links:

TheDaoIndex KDAO2011 ( View Tweet)

Clinical Pearl at #ACR21 from Dr. J. Stone: ⭐️Tissue biopsy is not essential in diagnosing IgG4-related dz in a pt w/ a typical pattern of retroperitoneal fibrosis. ⭐️Periaortitis ("coated" aorta) w/ "hairy" kidney is NOT IgG4 but rather Erdheim-Chester Dz #ACRBest @Rheumnow https://t.co/2tB9p3c7W7
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Abstr 0584 Patients in GLORIA Study noted to have - High number of comorbidities (median 6) - Multiple medications notably HTN and GI protection Findings represent medical reality of elderly RA patients (>65 years old) #ACR21 @RheumNow https://t.co/2cOtO9MLNM

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)

#ACR21 #Abstr0858 Petri reported effect of #COVID and vaccination in #lupus cohort 💠No increase in activity post-infection 💠⬇️cutaneous activity 💠⬆️ aCL IgG and IgM post-infection, 💠No increase in SLE activity or aCL abs post-vaccination @RheumNow https://t.co/iAaIfzf33c https://t.co/hA6sk6icrs

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
CARRA STOP-JIA 400pts, Obs study w/ 3 treatments plans : -Step up -Early combination -Biologic first Which one do you think works best? I'd say none: overall 40-60% not achieving CDI off steroids at 24 months. Results: 42% for SU, 52% EC, and 44% BF #Abtr0960 #ACR21 @RheumNow

Aurelie Najm AurelieRheumo ( View Tweet)

Are these pictures representative of a Sjogren's tongue or oral candidiasis? Comment below with your thoughts! #ACR21 #ClinicalPearls @RheumNow https://t.co/yGHA0pA7w0
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
7S125 Interesting talk on Anatomy for the Clinician: Putting Your Best Foot Forward #ACR21 @RheumNow https://t.co/zLbDW9yfEb
Akhil Sood MD AkhilSoodMD ( View Tweet)
Awesome presentation today from Dr. Cristina Ruiz-Romero on lipidomic profiles in RA vs PsA. Using mass spectrometry, found differences in both synovial bx and fluid. Potentially useful lipid markers, more studies to follow. #ACR21 #ACRBest Abst#0946 @RheumNow https://t.co/KmWCPKijSx
Pedro Castillo _Castillo_Pedro ( View Tweet)
Andy 0963 #ACR21 @RheumNow covid19 vaccine immunogenicity in rheum pts overall good at 71%, fairly dependent on Rx choice: rituximab 38% after 1g & only 7 % after 1gx2; abatacept IV 45%. Rest biologics >80%, ⬇️MTX &MMF. Low dose prednisone w/out biologics did not affect Ab+ rates https://t.co/TkCC1sgMHG
Olga Petryna DrPetryna ( View Tweet)
Infx oral session 0964 Bitoun, et al. RTX lowers neutralizing Ab response compared to healthy controls, after COVID vaccination -- more supportive data https://t.co/6jvWHSjIgr #ACR21

Links:

Rheum Cat rheum_cat ( View Tweet)

#ultrasound led to a change in Dx or Tx 2/3 of the time in a Sports Med clinic! #ACR21 #ACRAmbassador #POCUS https://t.co/2CviSOQKiz
Arthur Mandelin, MD/PhD, RhMSUS, RMSK NU_Rheum_MSK_US ( View Tweet)
Tofacitinib vs TNF inhibitors in #RA patients +50yrs with >1 CV risk factor; the data from ORAL Surveillance that we have all been waiting for! #ACR21 Risk of MACE related largely to baseline CV risk https://t.co/SpuKTtP8ql
The Lancet Rheumatology TheLancetRheum ( View Tweet)
To add numbers to this - using ARR because it's easiest: Vitamin D: 123/12,937 = 0.95% rheum dx Placebo: 155/12,937 = 1.20% rheum dx ARR = 0.25% or NNT of 400 to prevent 1 case of rheum dx Better get prescribing ASAP!

Mike Putman EBRheum ( View Tweet)

#ACR21 #ACRAmbassador Fascinating analysis of rheum dx from the (negative!) VITAL study (https://t.co/aMtMCIf1F1) Very few pts 278/25,871 (1.1%) but HR 0.78, p = 0.045 for vitamin D preventing autoimmune disease Do you believe it? If so, what's your public policy advice? https://t.co/ZkO5nHAJz9

Links:

Mike Putman EBRheum ( View Tweet)
ORAL-Surveillance, an open label Phase 3b/4 RCT of tofacitinib (JAKi) vs TNFi in RA Numerical elevations in MACE and MI, highest among pts w/hx of CAD or high 10-year risk for MACE I have been considering baseline CVD / VTE / CA risk when prescribing these since this broke https://t.co/8DAx8IgnZM
Mike Putman EBRheum ( View Tweet)
Dr Blazer sheds light on the multilayered SDOHs as they affect outcomes in chronic diseases. Head over to #ACR21 https://t.co/Jq7aiRV3MD
Chinny Jumai Osuorji,MD MediaRheum ( View Tweet)
Factors associated with Anti Drug Ab against TNFi over 2-y in axSpA pts are: ⭐️ 🔼 Disease activity ⭐️Development of adverse events ⭐️Treatment discontinuation Abst #0936 #ACR21 @RheumNow

swethaann23 swethaann23 ( View Tweet)

×